Business
Mesoblast scores US regulatory breakthrough – The Australian Financial Review
Mesoblast has scored a win in marketing its stem cell therapy drug in the US after a verdict was delivered about 7am AEST.
A US healthcare Oncologic Drugs Advisory Committee (ODAC) meeting has voted eight to two in favour of a Mesoblast drug to treat transplant rejections in children.
The verdict was delivered about 7am AEST after the US Food and Drug Administration’s (FDA) Advisory Committee majority voted the available clinical data supplied by Mesoblast support the efficacy of its Ryoncil drug in pediatric patients with acute-Graft Versus Host Disease (aGVHD).
The final decision on whether to approve Mesoblast’…
-
Noosa News20 hours agoChild, 15, arrested over death of another child, 8, after shocking e-bike crash in Queensland
-
General11 hours agoARIA Awards 2025 winners: Amyl & The Sniffers and Ninajirachi dominate
-
Noosa News18 hours agoDeath of German shepherd Arnie prompts Brisbane community action to protect pets caught up in crime
-
General13 hours agoPerth man charged after investigation into organised crime and tobacco store attacks